1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Japan Market Entry: Consortium’s One-Stop Shop To Support Foreign Entrants

JEC Aims To Help Ventures Without Presence

 
• By Lisa Takagi

Japanese CDMO Bushu talks about a consortium designed to provide a broad range of development services to smaller foreign firms looking to bring high-need drugs to the Japanese market.

Bushu
JEC started by several firms in market expertise in Japan including Bushu Pharma. (Shutterstock)

Japanese contract development and manufacturing organization (CDMO) Bushu Pharma and several of its peers are setting up a new one-stop service designed to provide a range of services to foreign ventures looking to bring their high-need drugs into the Japanese market.

Saitama-based Bushu, acquired by global private equity group KKR in 2023, has been enhancing its regulatory support offerings for foreign ventures in parallel with broader strategic efforts by Japan’s regulatory authorities to bridge the so-called “drug loss” issue,

Key Takeaways
  • To help foreign ventures aiming to enter the Japanese market, a Japanese CDMO Bushu and its peers started a one-stop service JEC covering market research, development, regulatory filing, production and marketing.
  • JEC removes the usual financial and regulatory uncertainty for newly entering foreign ventures by acting as its Japanese partner with its expertise in the market

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Japan Market Entry: Consortium’s One-Stop Shop To Support Foreign Entrants

 
• By Lisa Takagi

Japanese CDMO Bushu talks about a consortium designed to provide a broad range of development services to smaller foreign firms looking to bring high-need drugs to the Japanese market.

More from Business

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

Stock Watch: Bayer, Bavarian Nordic Bring European Cheer To Pharma

 
• By Andy Smith

Investors welcomed Bavarian Nordic’s and Bayer’s earnings announcements. However, both stock prices declined over the day of their reports as the impact of recent pressures weighed.

Mission Vision: How Roche Hopes To Impact Eye Health Outcomes In APAC

 
• By Anju Ghangurde

Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.